ST14

Across TCGA pan-cancer cohorts, ST14 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ST14 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ST14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ST14 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BRCA, ESCA, and LUSC are the cancer types where ST14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	II,III,IV	0.644	0.889	.008	20	view →
ESCA	DFS	Median	II,III,IV	0.187	0.525	.029	12	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
STAD	DFS	Median	II,III,IV	1.000	0.327	.040	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
GBM	DFS	Median	All	0.056	0.244	.005	3	view →
LGG	OS	Median	All	0.598	0.889	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ST14–BRCA (DFS)

Open the BRCA breakdown →